KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Revenue (2017 - 2025)

Sarepta Therapeutics (SRPT) has 12 years of Revenue data on record, last reported at $611.1 million in Q2 2025.

  • For Q2 2025, Revenue rose 69.49% year-over-year to $611.1 million; the TTM value through Dec 2025 reached $723.1 million, down 13.06%, while the annual FY2024 figure was $114.0 million, 90.83% down from the prior year.
  • Revenue reached $611.1 million in Q2 2025 per SRPT's latest filing, up from $112.0 million in the prior quarter.
  • Across five years, Revenue topped out at $1.1 billion in Q3 2024 and bottomed at -$1.0 billion in Q4 2024.
  • Average Revenue over 5 years is $210.1 million, with a median of $211.0 million recorded in 2022.
  • The widest YoY moves for Revenue: up 4760.81% in 2024, down 323.46% in 2024.
  • A 5-year view of Revenue shows it stood at $112.0 million in 2021, then surged by 51.09% to $169.2 million in 2022, then surged by 173.98% to $463.5 million in 2023, then crashed by 323.46% to -$1.0 billion in 2024, then soared by 159.0% to $611.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $611.1 million in Q2 2025, $112.0 million in Q1 2025, and -$1.0 billion in Q4 2024.